Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
51627-14-6N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3cn[nH]n3)CS[C@H]12)c1ccc(O)cc1UOCJDOLVGGIYIQ-PBFPGSCMSA-N51627-14-6DTXSID7022752CHEMBL1095284CHEBI:131730Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungCefatrizine was synthesized by BristolMyers Co. and Smith Klein & French Laboratories in 1974. It shows two to four times higher activity against gram-positive and four to eight times higher activity against gram-negative bacteria than cephalexin. Cefatrizine also shows excellent oral absorption, and its in vivo activity is 30 to 500 times higher than that of cephalexin.
VerwendenCefatrizine is a new orally administered cephalosporin with excellent activity against gram-positive cocci, inhibiting all except enterococci at minimal inhibitory concentrations below 1 μg/ml.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
DefinitionChEBI: A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be n inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.